secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001724521-24-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q4 net loss $81M; cash to $1.2B after Gilead; streamlines TIGIT program; casdatifan shows promise
--------------------------------------------------------------------------------

- Net loss of $81M in Q4 2023 ($307M full year); revenue $31M Q4 2023 vs $34M Q4 2022.
- Pro forma cash $1.2B after $320M equity investment from Gilead in Jan 2024; funding into 2027.
- Discontinued ARC-10 Phase 3 in PD-L1-high NSCLC; accelerating STAR-121; planning STAR-131 in perioperative NSCLC.
- Casdatifan (HIF-2a) Phase 1 data: 20 mg dose achieved similar EPO suppression as 120 mg belzutifan; no DLTs.
- Quemliclustat in pancreatic cancer: median OS 15.7 months in pooled ARC-8 analysis; Phase 3 planned early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000050/0001724521-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000050/rcus-20240221.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer